1. Home
  2. CBIO vs GAIA Comparison

CBIO vs GAIA Comparison

Compare CBIO & GAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • GAIA
  • Stock Information
  • Founded
  • CBIO 2003
  • GAIA 1988
  • Country
  • CBIO United States
  • GAIA United States
  • Employees
  • CBIO N/A
  • GAIA N/A
  • Industry
  • CBIO
  • GAIA Movies/Entertainment
  • Sector
  • CBIO
  • GAIA Consumer Discretionary
  • Exchange
  • CBIO Nasdaq
  • GAIA Nasdaq
  • Market Cap
  • CBIO 173.5M
  • GAIA 154.9M
  • IPO Year
  • CBIO N/A
  • GAIA 1999
  • Fundamental
  • Price
  • CBIO $12.94
  • GAIA $6.04
  • Analyst Decision
  • CBIO Strong Buy
  • GAIA Strong Buy
  • Analyst Count
  • CBIO 5
  • GAIA 2
  • Target Price
  • CBIO $25.60
  • GAIA $8.00
  • AVG Volume (30 Days)
  • CBIO 99.7K
  • GAIA 32.7K
  • Earning Date
  • CBIO 07-31-2025
  • GAIA 11-03-2025
  • Dividend Yield
  • CBIO N/A
  • GAIA N/A
  • EPS Growth
  • CBIO N/A
  • GAIA N/A
  • EPS
  • CBIO N/A
  • GAIA N/A
  • Revenue
  • CBIO N/A
  • GAIA $95,666,000.00
  • Revenue This Year
  • CBIO N/A
  • GAIA $13.81
  • Revenue Next Year
  • CBIO N/A
  • GAIA $15.74
  • P/E Ratio
  • CBIO N/A
  • GAIA N/A
  • Revenue Growth
  • CBIO N/A
  • GAIA 13.74
  • 52 Week Low
  • CBIO $10.83
  • GAIA $2.93
  • 52 Week High
  • CBIO $21.40
  • GAIA $6.53
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 47.01
  • GAIA 64.19
  • Support Level
  • CBIO $12.03
  • GAIA $5.79
  • Resistance Level
  • CBIO $13.21
  • GAIA $6.20
  • Average True Range (ATR)
  • CBIO 0.85
  • GAIA 0.25
  • MACD
  • CBIO -0.07
  • GAIA -0.01
  • Stochastic Oscillator
  • CBIO 33.58
  • GAIA 77.46

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About GAIA Gaia Inc.

Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an International presence.

Share on Social Networks: